Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities

Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced that results from the company’s first Phase 3 PROCEED study (Study 302; NCT01811732) were published in the Journal of Antimicrobial Chemotherapy. Study 302 was a multicenter, randomized, double-blind, active-controlled study that evaluated Baxdela™ (delafloxacin) compared with the combination regimen of vancomycin and aztreonam in 660 patients with ABSSSI (acute bacterial skin & skin structure infections). In assessment of the key endpoint, Baxdela was noninferior to vancomycin / aztreonam combination therapy in the Objective Response, showing reduction of at least 20% in lesion size at 48-to-72 hours, thereby meeting the primary endpoint.